Clinical Trial Update: A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating efficacy and safety of CP-690,550 (tofacitinib) in Asian subjects with moderate to severe psoriasis completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• CP-690,550 (tofacitinib)

Snippet

Sponsor: Pfizer | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-03-05